Hematopoietic-substrate-1 Associated Protein X-1 (HAX-1) Regulates Liver Cancer Cells Growth, Metastasis, and Angiogenesis Through Akt

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2019 May 28

PMID 31132019

Citations 6

Authors

Zhenyu Wu

Xiangnan Ai

Hao Hu

Siqi Wang

Yang Wang

Feng Kang

Caiguo Ouyang

Jiye Zhu

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the effects and mechanisms of hematopoietic-substrate-1-associated protein X-1 (HAX-1) on liver cancer cells. Information on HAX-1 from liver cancer patients was analyzed by the Cancer Genome Atlas (TCGA) program. Cell migration and invasion abilities were respectively tested by scratch assay and transwell assay. Tube formation assay was applied to detect angiogenesis protein and mRNA was determined using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. We found that the median month survival of HAX-1 overexpressing liver cancer patients was shorter than that of HAX-1 normal liver cancer patients. HAX-1 was overexpressed in liver cancer tissues and cells, and HAX-1 overexpression promoted the liver cancer cells growth, migration, and invasion, whereas silencing HAX-1 produced the opposite results. Inhibition of Akt by LY294002 reversed the migration and invasion abilities of liver cancer cells, and inhibited the ability of cells growth and angiogenesis. Silencing PIK3CA enhanced the inhibitory effects of HAX-1 silencing on the viability, migration, and invasion of liver cancer cells. HAX-1 affected liver cancer cells metastasis and angiogenesis by affecting Akt phosphorylation and FOXO3A expression.

Citing Articles

Anti-apoptotic HAX-1 suppresses cell apoptosis by promoting c-Abl kinase-involved ROS clearance.

Dong Q, Li D, Zhao H, Zhang X, Liu Y, Hu Y Cell Death Dis. 2022; 13(4):298.

PMID: 35379774 PMC: 8979985. DOI: 10.1038/s41419-022-04748-2.

HAX-1 overexpression in gastric cancer promotes cell proliferation.

Gu S, Zhang S, Huang H, Wang Q, Fan H, Shao Q Transl Cancer Res. 2022; 9(4):2672-2682.

PMID: 35117626 PMC: 8798389. DOI: 10.21037/tcr.2020.02.69.

HAX1 maintains the glioma progression in hypoxia through promoting mitochondrial fission.

Lin J, Wang Y, Lin Z J Cell Mol Med. 2021; 25(24):11170-11184.

PMID: 34755451 PMC: 8650040. DOI: 10.1111/jcmm.17038.

QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis.

Zhao T, Zhou Y, Wang Q, Yi X, Ge S, He H Int J Oncol. 2021; 59(1).

PMID: 34036385 PMC: 8208629. DOI: 10.3892/ijo.2021.5228.

Expression of Integrin β6 and HAX-1 Correlates with Aggressive Features and Poor Prognosis in Esophageal Squamous Cell Carcinoma.

Li F, Shang Y, Shi F, Zhang L, Yan J, Sun Q Cancer Manag Res. 2020; 12:9599-9608.

PMID: 33061645 PMC: 7537805. DOI: 10.2147/CMAR.S274892.

References

Yuan J, Govindarajan S, Arakawa K, Yu M . Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer. 2004; 101(5):1009-17. DOI: 10.1002/cncr.20427. View

Chen J, Wang Q, Fu X, Huang X, Chen X, Cao L . Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res. 2009; 39(2):177-86. DOI: 10.1111/j.1872-034X.2008.00449.x. View

Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y . TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463(7281):676-80. DOI: 10.1038/nature08734. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Kashiwagi A, Fein M, Shimada M . Calpain modulates cyclin-dependent kinase inhibitor 1B (p27(Kip1)) in cells of the osteoblast lineage. Calcif Tissue Int. 2011; 89(1):36-42. PMC: 3111891. DOI: 10.1007/s00223-011-9491-3. View

Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y . The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncol Rep. 2012; 27(6):1703-9. DOI: 10.3892/or.2012.1724. View

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

Lam C, Zhao W, Cai W, Vafiadaki E, Florea S, Ren X . Novel role of HAX-1 in ischemic injury protection involvement of heat shock protein 90. Circ Res. 2012; 112(1):79-89. PMC: 3537902. DOI: 10.1161/CIRCRESAHA.112.279935. View

Wang S, Chong Z, Shang Y, Maiese K . WISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1. Curr Neurovasc Res. 2012; 10(1):54-69. PMC: 3568221. DOI: 10.2174/156720213804805945. View

10.

Li M, Tang Y, Zang W, Xuan X, Wang N, Ma Y . Analysis of HAX-1 gene expression in esophageal squamous cell carcinoma. Diagn Pathol. 2013; 8:47. PMC: 3617057. DOI: 10.1186/1746-1596-8-47. View

11.

Li T, Dong Z, Guo Z, Wang C, Tang Z, Qu S . Aspirin enhances IFN-α-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway. Cancer Gene Ther. 2013; 20(6):366-74. DOI: 10.1038/cgt.2013.29. View

12.

Trebinska A, Konopinski R, Grzybowska E . Comment on "HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor". J Oncol. 2013; 2013:782327. PMC: 3674746. DOI: 10.1155/2013/782327. View

13.

Wei X, Li S, Yu B, Chen G, Du J, Cai H . Expression of HAX-1 in human colorectal cancer and its clinical significance. Tumour Biol. 2013; 35(2):1411-5. DOI: 10.1007/s13277-013-1194-0. View

14.

Wang J, Zheng X, Zeng G, Zhou Y, Yuan H . Purified vitexin compound 1 inhibits growth and angiogenesis through activation of FOXO3a by inactivation of Akt in hepatocellular carcinoma. Int J Mol Med. 2013; 33(2):441-8. DOI: 10.3892/ijmm.2013.1587. View

15.

Carbajo-Pescador S, Mauriz J, Garcia-Palomo A, Gonzalez-Gallego J . FoxO proteins: regulation and molecular targets in liver cancer. Curr Med Chem. 2013; 21(10):1231-46. DOI: 10.2174/0929867321666131228205703. View

16.

Bruix J, Gores G, Mazzaferro V . Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5):844-55. PMC: 4337888. DOI: 10.1136/gutjnl-2013-306627. View

17.

Gomathinayagam R, Muralidharan J, Ha J, Varadarajalu L, Dhanasekaran D . Hax-1 is required for Rac1-Cortactin interaction and ovarian carcinoma cell migration. Genes Cancer. 2014; 5(3-4):84-99. PMC: 4091533. DOI: 10.18632/genesandcancer.8. View

18.

Wang M, Meng X, Yu Y, Sun G, Xu X, Zhang X . Elatoside C protects against hypoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes through the reduction of endoplasmic reticulum stress partially depending on STAT3 activation. Apoptosis. 2014; 19(12):1727-35. DOI: 10.1007/s10495-014-1039-3. View

19.

Baumann U, Fernandez-Saiz V, Rudelius M, Lemeer S, Rad R, Knorn A . Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nat Med. 2014; 20(12):1401-9. DOI: 10.1038/nm.3740. View

20.

Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H . Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer. 2015; 112(3):532-8. PMC: 4453648. DOI: 10.1038/bjc.2014.621. View